Brian J. Druker
| Brian J. Druker | |
|---|---|
 |
|
| Born | April 30, 1955 |
| Nationality | American |
| Institutions | Howard Hughes Medical Institute, Oregon Health & Science University |
| Alma mater | University of California, San Diego |
| Known for | Gleevec |
| Notable awards |
Robert Koch Prize (2005) Keio Medical Science Prize (2007) Meyenburg Award (2009) Lasker Clinical Award (2009) Japan Prize (2012) Dickson Prize (2012) Albany Medical Center Prize (2013) Sheikh Hamdan bin Rashid Al Maktoum Award for Medical Sciences (2013-14) |
Brian J. Druker (born April 30, 1955) is a physician-scientist at Oregon Health & Science University, in Portland, Oregon. He is the director of OHSU's Knight Cancer Institute, Jeld-Wen Chair of Leukemia Research, and professor of medicine. In 2009, he won the Lasker-DeBakey Clinical Medical Research Award and the Meyenburg Award for his influential work in the development of Imatinib (or STI571), commonly known as Gleevec, for the treatment of chronic myeloid leukemia (CML). He has been called "Oregon's best-known scientist".
Druker earned both his B.S. degree in chemistry and M.D. degree from the University of California, San Diego. He completed internship and residency in internal medicine at Barnes Hospital, Washington University School of Medicine in St. Louis from 1981 to 1984.
Druker was a fellow in medical oncology at Dana–Farber Cancer Institute, Harvard Medical School, from 1984 to 1987. He began working at Oregon Health & Science University (OHSU) in 1993.
In May 2007, he became director of the OHSU Cancer Institute—renamed the Knight Cancer Institute in October 2008 following a $100 million donation from Nike co-founder Phil Knight.
...
Wikipedia